TapewireFind a company

person · Reporting owner

BELANOFF JOSEPH K

Disclosed activity across 1 company

Tapewire entity
42541
SEC CIK
0001286199

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
CORCEPT THERAPEUTICS INCCORT · Entity 2620Director · Chief Executive OfficerMay 29, 2026June 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CORCEPT THERAPEUTICS INC

Report date May 29, 2026 · Filed June 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectJoseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/022,565,489 Last balance in matching sequence After 2026-06-01 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2026-05-29 · Gift · Disposed 300,000 · Balance 2,578,326

F1: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Row 4 · 2026-06-01 · Sale · Disposed 12,837 · Balance 2,565,489

F6: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F1: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectJoseph K. Belanoff 2026 Grantor Retained Annuity Trust150,000 Reported balance After 2026-05-29 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2026-05-29 · Gift · Acquired 150,000 · Balance 150,000

F2: Transfer of shares without consideration to the Joseph K. Belanoff 2026 Grantor Retained Annuity Trust.

F3: Shares are held by Joseph K. Belanoff 2026 Grantor Retained Annuity Trust, of which the Reporting Person is the trustee.

Common StockSEC Table I · non-derivativeIndirectKatherine A. Blenko 2026 Grantor Retained Annuity Trust150,000 Reported balance After 2026-05-29 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 3 · 2026-05-29 · Gift · Acquired 150,000 · Balance 150,000

F4: Transfer of shares without consideration to the Katherine A. Blenko 2026 Grantor Retained Annuity Trust.

F5: Shares are held by Katherine A. Blenko 2026 Grantor Retained Annuity Trust, of which the spouse of the Reporting Person is the trustee.

Filing footnotes · ownership attribution and instrument terms

F1: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

F2: Transfer of shares without consideration to the Joseph K. Belanoff 2026 Grantor Retained Annuity Trust.

F3: Shares are held by Joseph K. Belanoff 2026 Grantor Retained Annuity Trust, of which the Reporting Person is the trustee.

F4: Transfer of shares without consideration to the Katherine A. Blenko 2026 Grantor Retained Annuity Trust.

F5: Shares are held by Katherine A. Blenko 2026 Grantor Retained Annuity Trust, of which the spouse of the Reporting Person is the trustee.

F6: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 01, 2026 Filed Jun 2, 2026 20:05 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 12,837 $69.74 $895,252.38
Disclosure

SEC source: 0001193125-26-253459 · ownership.xml · nonDerivative · entry 4

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,565,489

F6 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F1 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
May 29, 2026 Filed Jun 2, 2026 20:05 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 150,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-253459 · ownership.xml · nonDerivative · entry 3

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Katherine A. Blenko 2026 Grantor Retained Annuity Trust

Disclosed balance after: 150,000

F4 · kind: Transfer of shares without consideration to the Katherine A. Blenko 2026 Grantor Retained Annuity Trust.

F5 · ownership.nature: Shares are held by Katherine A. Blenko 2026 Grantor Retained Annuity Trust, of which the spouse of the Reporting Person is the trustee.

Read SEC document
May 29, 2026 Filed Jun 2, 2026 20:05 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 150,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-253459 · ownership.xml · nonDerivative · entry 2

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff 2026 Grantor Retained Annuity Trust

Disclosed balance after: 150,000

F2 · kind: Transfer of shares without consideration to the Joseph K. Belanoff 2026 Grantor Retained Annuity Trust.

F3 · ownership.nature: Shares are held by Joseph K. Belanoff 2026 Grantor Retained Annuity Trust, of which the Reporting Person is the trustee.

Read SEC document
May 29, 2026 Filed Jun 2, 2026 20:05 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 300,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-253459 · ownership.xml · nonDerivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,578,326

F1 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
May 01, 2026 Filed May 5, 2026 20:30 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 40,000 $50.10 $2,003,860.00
Disclosure

SEC source: 0001193125-26-206540 · ownership.xml · nonDerivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,878,326

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.00 to $50.35 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
March 25, 2026 Filed Mar 27, 2026 20:27 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 26,198 $50.07 $1,311,825.55
Disclosure

SEC source: 0001193125-26-129143 · ownership.xml · nonDerivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,918,326

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.00 to $50.32 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
February 27, 2026 Filed Mar 3, 2026 23:17 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GrantStock Option (right to buy) · Derivative 460,000 $0.00 Strike: $35.70 $0.00
Disclosure

SEC source: 0001193125-26-089023 · ownership.xml · derivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 460,000

Underlying: Common Stock · 460,000 shares

Expires 2036-02-27

F1 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date.

Read SEC document
December 24, 2025 Filed Dec 29, 2025 22:24 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 Exercise / conversionStock option (right to buy) · Derivative 550,000 $0.00 Strike: $3.88 $0.00
Disclosure

SEC source: 0001193125-25-335538 · ownership.xml · derivative · entry 5

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 550,000 shares

Expires 2026-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully exercisable.

Read SEC document
December 24, 2025 Filed Dec 29, 2025 22:24 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 OtherCommon Stock 243,154 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-335538 · ownership.xml · nonDerivative · entry 4

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,944,524

F2 · kind: Transfer of shares without consideration to the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
December 24, 2025 Filed Dec 29, 2025 22:24 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 243,154 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-335538 · ownership.xml · nonDerivative · entry 3

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Read SEC document
December 24, 2025 Filed Dec 29, 2025 22:24 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 Tax withholdingCommon Stock 306,846 $83.59 $25,649,257.14
Disclosure

SEC source: 0001193125-25-335538 · ownership.xml · nonDerivative · entry 2

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 243,154

F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability from a net (cashless) exercise of options.

Read SEC document
December 24, 2025 Filed Dec 29, 2025 22:24 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 Exercise / conversionCommon Stock 550,000 $3.88 $2,134,000.00
Disclosure

SEC source: 0001193125-25-335538 · ownership.xml · nonDerivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 550,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 01, 2025 Filed Dec 4, 2025 01:14 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 40,000 $79.77 $3,190,796.00
Disclosure

SEC source: 0001193125-25-307204 · ownership.xml · nonDerivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,701,370

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.65 to $79.97 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
November 05, 2025 Filed Nov 6, 2025 00:57 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 3,590 $75.98 $272,759.94
Disclosure

SEC source: 0001193125-25-267545 · ownership.xml · nonDerivative · entry 4

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,741,370

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F6 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $75.725 to $76.28 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
November 05, 2025 Filed Nov 6, 2025 00:57 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 10,837 $75.14 $814,261.84
Disclosure

SEC source: 0001193125-25-267545 · ownership.xml · nonDerivative · entry 3

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,744,960

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $74.72 to $75.71 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
November 05, 2025 Filed Nov 6, 2025 00:57 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 14,355 $74.20 $1,065,083.58
Disclosure

SEC source: 0001193125-25-267545 · ownership.xml · nonDerivative · entry 2

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,755,797

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.72 to $74.70 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
November 03, 2025 Filed Nov 6, 2025 00:57 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 11,218 $74.08 $831,013.73
Disclosure

SEC source: 0001193125-25-267545 · ownership.xml · nonDerivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,770,152

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.74 to $74.26 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
October 01, 2025 Filed Oct 3, 2025 21:24 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 3,194 $85.67 $273,617.84
Disclosure

SEC source: 0001193125-25-230467 · ownership.xml · nonDerivative · entry 3

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,781,370

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $85.63 to $85.785 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
October 01, 2025 Filed Oct 3, 2025 21:24 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 31,190 $85.16 $2,656,265.16
Disclosure

SEC source: 0001193125-25-230467 · ownership.xml · nonDerivative · entry 2

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,784,564

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $84.5875 to $85.575 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
October 01, 2025 Filed Oct 3, 2025 21:24 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 5,616 $84.29 $473,369.83
Disclosure

SEC source: 0001193125-25-230467 · ownership.xml · nonDerivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,815,754

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.58 to $84.53 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
September 02, 2025 Filed Sep 4, 2025 23:54 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 700 $71.01 $49,707.49
Disclosure

SEC source: 0001193125-25-196313 · ownership.xml · nonDerivative · entry 2

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,821,370

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.97 to $71.085 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
September 02, 2025 Filed Sep 4, 2025 23:54 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 39,300 $70.52 $2,771,325.96
Disclosure

SEC source: 0001193125-25-196313 · ownership.xml · nonDerivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,822,070

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.97 to $70.96 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
August 01, 2025 Filed Aug 5, 2025 22:51 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 5,446 $69.65 $379,304.64
Disclosure

SEC source: 0000950170-25-103323 · ownership.xml · nonDerivative · entry 3

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,861,370

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.4412 to $69.77 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
August 01, 2025 Filed Aug 5, 2025 22:51 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 17,809 $68.87 $1,226,486.24
Disclosure

SEC source: 0000950170-25-103323 · ownership.xml · nonDerivative · entry 2

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,866,816

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $68.43 to $69.42 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
August 01, 2025 Filed Aug 5, 2025 22:51 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 16,745 $67.81 $1,135,416.49
Disclosure

SEC source: 0000950170-25-103323 · ownership.xml · nonDerivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,884,625

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $67.42 to $68.33 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
July 17, 2025 Filed Jul 21, 2025 23:11 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 615 $73.69 $45,317.69
Disclosure

SEC source: 0000950170-25-097372 · ownership.xml · nonDerivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,901,370

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.655 to $73.74 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:41 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 8,408 $85.01 $714,777.53
Disclosure

SEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 8

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,901,985

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F10 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $85.00 to $85.31 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:41 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 12,959 $84.57 $1,095,962.07
Disclosure

SEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 7

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,910,393

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F9 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.975 to $84.94 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:41 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 4,631 $83.46 $386,523.17
Disclosure

SEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 6

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,923,352

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F8 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $82.96 to $83.95 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:41 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 1,263 $82.26 $103,898.67
Disclosure

SEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 5

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,927,983

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F7 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.935 to $82.80 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:41 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 1,820 $81.33 $148,012.41
Disclosure

SEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 4

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,929,246

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F6 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.92 to $81.78 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:41 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 2,988 $80.30 $239,941.48
Disclosure

SEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 3

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,931,066

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.90 to $80.8925 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:41 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 3,050 $79.48 $242,421.02
Disclosure

SEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 2

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,934,054

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $78.88 to $79.865 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:41 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 4,881 $78.42 $382,773.39
Disclosure

SEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,937,104

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $77.84 to $78.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
May 02, 2025 Filed May 6, 2025 00:28 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 21,520 $73.22 $1,575,776.18
Disclosure

SEC source: 0000950170-25-063831 · ownership.xml · nonDerivative · entry 2

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,941,985

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.00 to $73.65 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
May 02, 2025 Filed May 6, 2025 00:28 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 18,480 $72.52 $1,340,145.58
Disclosure

SEC source: 0000950170-25-063831 · ownership.xml · nonDerivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,963,505

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $72.13 to $72.99 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 00:01 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 350 $114.71 $40,148.50
Disclosure

SEC source: 0000950170-25-049790 · ownership.xml · nonDerivative · entry 2

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,981,985

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F2 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
March 31, 2025 Filed Apr 3, 2025 00:01 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 35,102 $94.72 $3,324,861.44
Disclosure

SEC source: 0000950170-25-049790 · ownership.xml · nonDerivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,982,335

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F2 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
March 24, 2025 Filed Mar 26, 2025 21:07 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 1,974 $60.83 $120,084.14
Disclosure

SEC source: 0000950170-25-045433 · ownership.xml · nonDerivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 3,017,437

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $60.83 to $60.93 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 00:44 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 2,924 $60.91 $178,097.92
Disclosure

SEC source: 0000950170-25-032740 · ownership.xml · nonDerivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 3,019,411

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $60.83 to $61.045 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
February 28, 2025 Filed Mar 5, 2025 00:44 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GrantStock option (right to buy) · Derivative 350,000 $0.00 Strike: $60.58 $0.00
Disclosure

SEC source: 0000950170-25-032740 · ownership.xml · derivative · entry 2

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2035-02-28

F4 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date.

Read SEC document
July 31, 2024 Filed Aug 2, 2024 20:42 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 Exercise / conversionStock option (right to buy) · Derivative 450,000 $0.00 Strike: $3.29 $0.00
Disclosure

SEC source: 0000950170-24-090052 · ownership.xml · derivative · entry 4

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 450,000 shares

Expires 2025-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Fully exercisable.

Read SEC document
July 31, 2024 Filed Aug 2, 2024 20:42 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 Tax withholdingCommon Stock 259,583 $38.67 $10,038,074.61
Disclosure

SEC source: 0000950170-24-090052 · ownership.xml · nonDerivative · entry 2

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 539,228

F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on July 31, 2024. The options subject to the net exercise were to expire on February 18, 2025.

Read SEC document
July 31, 2024 Filed Aug 2, 2024 20:42 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 Exercise / conversionCommon Stock 450,000 $3.29 $1,480,500.00
Disclosure

SEC source: 0000950170-24-090052 · ownership.xml · nonDerivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 798,811

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 31, 2024 Filed Feb 14, 2025 21:40 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 OtherCommon Stock 190,417 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-021329 · ownership.xml · nonDerivative · entry 4

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 3,022,335

F1 · kind: Transfer of shares without consideration to the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02.

F2 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

F3 · ownership.nature: Due to an administrative error, prior reporting of the name of this trust has been corrected. The exact name of the trust, "Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02" was mistakenly identified as the "Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 01/29/02".

Read SEC document
July 31, 2024 Filed Feb 14, 2025 21:40 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 190,417 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-021329 · ownership.xml · nonDerivative · entry 3

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Read SEC document
February 09, 2024 Filed Feb 14, 2024 01:25 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GrantStock option (right to buy) · Derivative 500,000 $0.00 Strike: $23.01 $0.00
Disclosure

SEC source: 0000950170-24-014879 · ownership.xml · derivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2034-02-09

F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 9, 2024 over a four-year period.

Read SEC document
February 13, 2023 Filed Feb 16, 2023 00:59 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GrantStock option (right to buy) · Derivative 500,000 $0.00 Strike: $23.06 $0.00
Disclosure

SEC source: 0000899243-23-005173 · doc4.xml · derivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2033-02-12

F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 13, 2023 over a four-year period.

Read SEC document
July 07, 2022 Filed Jul 8, 2022 21:20 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 55,111 $26.26 $1,446,944.82
Disclosure

SEC source: 0000899243-22-025827 · doc4.xml · nonDerivative · entry 4

BELANOFF JOSEPH K · CIK 0001286199 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 01/29/02

Disclosed balance after: 2,483,107

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2022, as amended.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $26.21 to $26.41. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

F5 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 01/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
July 06, 2022 Filed Jul 8, 2022 21:20 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 Exercise / conversionStock option (right to buy) · Derivative 800,000 $0.00 Strike: $2.08 $0.00
Disclosure

SEC source: 0000899243-22-025827 · doc4.xml · derivative · entry 5

BELANOFF JOSEPH K · CIK 0001286199 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 800,000 shares

Expires 2023-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Fully exercisable.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.